Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue: +39.2%
EPS: +45.6%
Free cash flow: −58.6%
Total debt: +115.1%

Quarter to September 2026, against a year earlier

104.29 18.67 −15.18%

Follow HALO

Alert me

Market cap: $14.0B
P/E: 29.5×
Fwd P/E: 17.9×
Dividend yield: —
F-score: 5/9
Altman Z: 3.46
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Halozyme Therapeutics, Inc. (HALO) P/B ratio

Alert me on P/B ratio

Halozyme Therapeutics, Inc. has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 199× (February 2026) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/HALO/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Halozyme Therapeutics, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/HALO/metrics/pb-ratio">Halozyme Therapeutics, Inc. (HALO) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	165×	891.36%
FY2024	16.7×	(71.68%)
FY2023	58.9×	32.47%
FY2022	44.4×	54.73%
FY2021	28.7×	(25.44%)
FY2020	38.5×	38.11%
FY2019	27.9×	230.36%
FY2018	8.4×	(36.17%)
FY2017	13.2×	—
FY2016	0.0×	—

Period	P/B ratio	Change
Sep 2026	0.0×	—
Jun 2026	63.9×	83.94%
Mar 2026	34.8×	(78.96%)
Dec 2025	165×	868.48%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 199×

Ten-year median 28.2×

Current reading's percentile 7

Company	P/B ratio
HALO Halozyme Therapeutics, Inc.	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	1.7×
JAZZ Jazz Pharmaceuticals PLC compare	3.5×
TECH Bio-Techne Corp compare	5.4×
KYMR Kymera Therapeutics, Inc. compare	7.8×
EXEL Exelixis, Inc. compare	9.3×
ASND Ascendis Pharma A/S compare	9.8×
SMMT Summit Therapeutics PLC compare	17.8×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Halozyme Therapeutics, Inc. (HALO) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on HALO

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on HALO

Stockrow Weekly